Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar
Alvotech and Teva this week saw promising clinical trial results for their biosimilar to Stelara, Johnson & Johnson’s blockbuster immunology drug. The trial, which compared Stelara and candidate AVT04, found “no clinically meaningful differences in safety” between the two IL-12 and IL-23 inhibitors. Stelara launched in 2009 as a therapy for moderate to severe plaque psoriasis, and has since expanded across the immunology space. For the treatment of psoriasis, virtually all insured lives (99%) have covered or better access to Stelara under the pharmacy benefit. About 40% of covered lives have preferred access to Stelara, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 5/25/22